Vivet’s VTX-801 gene therapy gets FDA fast track status in Wilson Disease
Vivet Therapeutics, a biotech company backed by Pfizer, has been given fast track designation by the US Food and Drug Administration for its gene therapy candidate VTX-801 for the treatment of Wilson Disease. Wilson Disease is a rare, genetic disorder that lessens the ability of the liver and other tissues in controlling copper levels, thereby […]